What EBITDA Multiple Will a DSO Pay for My Dental Practice?

DentalDex · Valuation guides · 2 min read · Methodology

DSO dental-practice valuations are commonly discussed as a multiple of normalized EBITDA. A broad planning range may fall around 4x to 9x EBITDA, but actual offers can fall below or above that range depending on size, specialty, growth, provider dependency, geography and deal structure.

These numbers should be treated as market-education ranges rather than guaranteed pricing.

EBITDA size matters

All else equal, larger EBITDA businesses frequently command stronger multiples because they offer buyers greater scale. An illustrative framework might look like:

Normalized EBITDA	Illustrative DSO range
Below $250K	Limited institutional market; roughly 3.5x–5x
$250K–$500K	Roughly 4x–6x
$500K–$1M	Roughly 5x–7.5x
$1M+	Roughly 6x–9x+

These are not quotes. Different buyers may value the same practice very differently.

Why bigger practices often get higher multiples

A $1 million EBITDA practice is not simply twice as valuable as a $500,000 EBITDA practice. The larger platform may:

• support management infrastructure
• justify specialty expansion
• attract a larger buyer universe
• have multiple providers
• produce more integration savings
• carry less relative overhead risk

That can create multiple expansion as EBITDA grows.

Specialty matters

Some specialties attract different buyer populations and valuation ranges. Orthodontics, oral surgery, pediatric dentistry, endodontics and other specialty practices may trade differently from general dentistry depending on referral relationships, doctor dependency and available DSO buyers.

Owner dependency matters

A six-times multiple on $600,000 EBITDA may look attractive. But if the seller generates 90% of production and plans to leave in six months, a buyer may reduce the multiple, the cash at closing, or both. Another buyer may still offer an attractive headline valuation but require a longer employment commitment.

Growth matters

Buyers generally prefer acquiring $500K EBITDA growing 12% over $500K EBITDA declining 10%, even though the trailing EBITDA is identical. Valuation is forward-looking.

The highest multiple is not necessarily the best deal

Compare:

Buyer A: 7x EBITDA with substantial rollover equity and a five-year employment requirement.

Buyer B: 6.5x EBITDA with more cash at closing and a shorter employment requirement.

The correct decision depends on the seller's objectives. That is why DentalDex emphasizes offer economics, not just multiples.

Market ranges on this page are illustrative planning ranges, not offers. Involve qualified legal and tax advisers on any transaction.